Press Release

Thursday, 11 May 2017

Spinoff company receives a boost worth millions

“We use what are known as non-coding ribonucleic acids (RNAs) to diagnose and treat heart conditions such as cardiac insufficiency,“ says Professor Thomas Thum, founder of a Hannover Medical School (MHH) spinoff company called Cardior Pharmaceuticals GmbH. (Thum is head of MHH’s Institute of Molecular and Translational Therapy Strategies (IMTTS) and of the REBIRTH unit on miRNA in Myocardial Regeneration.) In order to prevent or reduce cardiac insufficiency – i.e. heart failure – the heart’s muscle cells are enabled to reverse abnormal remodeling processes and to work normally once more. “Our therapeutic agents influence specific non-coding RNAs that control the growth and contractile ability of cardiac muscle cells, and which are instrumental in causing heart failure,” Professor Thum explains. He is convinced that groundbreaking therapies of this nature offer significant opportunities for patients with this weakening of the heart muscle, a condition with one of the highest fatality rates worldwide. Considerable funding (worth 15 million euros) will now enable Cardior to develop its first new lead substance further, meaning that initial clinical data can be obtained in the near future.

Download the press release (in German):
170511_Thum_Cardior.pdf